⌕
Collegium Pharmaceutical · COLL · Nasdaq
Tenet 60 · Solid
Compare
$25.55+0.47%At closeTenet 60 · Solid
$25.55+0.12 (+0.47%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Collegium Pharmaceutical (COLL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is COLL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 17, 2026 · 10:41 ET
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 10:56 ET
Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade

The mean of analysts' price targets for Collegium Pharmaceutical (COLL) points to an 81.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i…

COLL +0.5% todayRead at source ↗
● Seeking AlphaNov 7, 2026 · 21:14 ET
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director Colleen Tupper - Executive …

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 10:36 ET
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.…

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 10:31 ET
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimat…

COLL +0.5% todayRead at source ↗
● MarketBeatNov 5, 2026 · 10:15 ET
Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines. The company reaffirmed…

COLL +0.5% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Reve…

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 12:41 ET
COLL or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investor…

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 11:06 ET
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

COLL +0.5% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership combines youth coach tr…

COLL +0.5% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026

STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood …

COLL +0.5% todayRead at source ↗
● GlobeNewsWireOct 21, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses

Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults and…

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 19, 2026 · 12:40 ET
COLL vs. DSNKY: Which Stock Is the Better Value Option?

Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).…

COLL +0.5% todayRead at source ↗
● Seeking AlphaOct 17, 2026 · 12:18 ET
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account for over 30% of 2026 s…

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 10:55 ET
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r…

COLL +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 7, 2026 · 04:26 ET
New Strong Sell Stocks for October 7th

ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.…

COLL +0.5% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood …

COLL +0.5% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 20:01 ET
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

COLL +0.5% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood…

COLL +0.5% todayRead at source ↗
● Defense WorldAug 30, 2026 · 04:23 ET
44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP

Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fi…

COLL +0.5% todayRead at source ↗
● Defense WorldAug 28, 2026 · 04:12 ET
BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL

BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm boug…

COLL +0.5% todayRead at source ↗
● GuruFocusAug 27, 2026 · 20:19 ET
A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39

On August 27, 2026, Collegium Pharmaceutical Inc (COLL) shares fell 3.9% to a current price of $26.39. Over the past year, the stock has seen significant volati…

COLL +0.5% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%

Article counts from the last market-wide feed page, across every symbol we track and not just COLL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.